Hey everybody, it's David here, letting you know that we are launching our next round of

navigating psychedelics for clinicians and therapists. It starts on Wednesday, September the 14th,

and then meeting each week for nine weeks. And there are two groups with different time

slots you can choose from. So navigating psychedelics is the course that I took a couple of years

ago and it changed my

life and my career big time and now I have the pleasure of co-facilitating this round of the course

alongside our guest teachers, Jasmine Verdi and Sarah Reid. So if you want to find out more about

the syllabus and the structure of the course, go to

Psychedelic Education Centre.com.

And you can also sign up for a free Q&A webinar that we're offering every Wednesday until

the course starts.

To book your webinar spot, go to psychedelicsday.com forward slash events.

Hey everybody, welcome back to psychedelics today with your host, David Drapkin, having a chat today with Jim Gilligan of Trip Therapeutics. So Jim also lives in New Jersey

like me and we got to talk about his career and kind of how it's gone all over the place

the last 40 years. And since he's been working in the psychedelics world at Trip, the new research

that he plans on doing with the partners at the University of Michigan into

kind of pain disorders and at the University of Florida around overeating disorders.

Just how novel it is that they're doing kind of psychedelic, informed research around these

conditions that the medicines and practices treatments are not very effective

of right now and they haven't kind of evolved much over the last few years. So really cool to see

how psychedelic compounds can have benefits on non-mental health disorders. And great as well to see

that Jim is kind of combining his initial science and medicine

...